{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:32:28Z","timestamp":1792513948616,"version":"4.5.0"},"reference-count":115,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T00:00:00Z","timestamp":1523664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Cancer is a life-threatening disease contributing to ~3.4 million deaths worldwide. There are various causes of cancer, such as smoking, being overweight or obese, intake of processed meat, radiation, family history, stress, environmental factors, and chance. The first-line treatment of cancer is the surgical removal of solid tumours, radiation therapy, and chemotherapy. The systemic administration of the free drug is considered to be the main clinical failure of chemotherapy in cancer treatment, as limited drug concentration reaches the tumour site. Most of the active pharmaceutical ingredients (APIs) used in chemotherapy are highly cytotoxic to both cancer and normal cells. Accordingly, targeting the tumour vasculatures is essential for tumour treatment. In this context, encapsulation of anti-cancer drugs within the liposomal system offers secure platforms for the targeted delivery of anti-cancer drugs for the treatment of cancer. This, in turn, can be helpful for reducing the cytotoxic side effects of anti-cancer drugs on normal cells. This short-review focuses on the use of liposomes in anti-cancer drug delivery.<\/jats:p>","DOI":"10.3390\/molecules23040907","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T03:12:09Z","timestamp":1523848329000},"page":"907","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":559,"title":["Liposomal Drug Delivery Systems and Anticancer Drugs"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3565-2442","authenticated-orcid":false,"given":"Temidayo","family":"Olusanya","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland SR1 3SD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Haj Ahmad","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland SR1 3SD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ibegbu","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, College of Medicine, University of Nigeria Enugu Campus, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Smith","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0781-1127","authenticated-orcid":false,"given":"Amal","family":"Elkordy","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland SR1 3SD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8307","DOI":"10.1039\/c3nr01525d","article-title":"Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation","volume":"5","author":"Kumar","year":"2013","journal-title":"Nanoscale"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug Delivery Systems: Entering the Mainstream","volume":"303","author":"Allen","year":"2004","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_4","first-page":"85","article-title":"Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids","volume":"130","author":"Chan","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejpb.2017.02.001","article-title":"Formulation and ex vivo evaluation of polymeric nanoparticles for controlled delivery of corticosteroids to the skin and the corneal epithelium","volume":"115","author":"Balzus","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejpb.2017.06.016","article-title":"Electrically atomised formulations of timolol maleate for direct and on-demand ocular lens coatings","volume":"119","author":"Mehta","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_7","unstructured":"Chen, M.J., Hui, H.-W., Lee, T., Kurtulik, P., and Surapaneni, S. (2009). Nanosuspension of a Poorly Soluble Drug via Microfluidization Process. (9,023,886), U.S. Patent."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1021\/acs.molpharmaceut.7b00051","article-title":"Control of liposomal penetration into three-dimensional multicellular tumor spheroids by modulating liposomal membrane rigidity","volume":"14","author":"Goda","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-1-4831-9937-5.50008-9","article-title":"Physical structure and behavior of lipids and lipid enzymes","volume":"1","author":"Bangham","year":"1963","journal-title":"Adv. Lipid Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: Classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2004.07.010","article-title":"Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability","volume":"285","author":"Mohammed","year":"2004","journal-title":"Int. J. Pharm."},{"key":"ref_13","first-page":"213","article-title":"Sustained release of acyclovir from nano-liposomes and nano-niosomes: An in vitro study","volume":"2","author":"Mukherjee","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0165-6147(94)90314-X","article-title":"Long-circulating (sterically stabilized) liposomes for targeted drug delivery","volume":"15","author":"Allen","year":"1994","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","article-title":"Advantages of liposomal delivery systems for anthracyclines","volume":"31","author":"Allen","year":"2004","journal-title":"Semin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.colsurfb.2016.10.052","article-title":"Anticancer activity of all-trans retinoic acid-loaded liposomes on human thyroid carcinoma cells","volume":"150","author":"Cristiano","year":"2017","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/187152006778699121","article-title":"Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer","volume":"6","author":"Allen","year":"2006","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0168-3659(01)00460-6","article-title":"Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein","volume":"77","author":"Matsuo","year":"2001","journal-title":"J. Control. Release"},{"key":"ref_19","first-page":"1565","article-title":"Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride","volume":"45","author":"Wang","year":"2010","journal-title":"Yao Xue Xue Bao"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.reactfunctpolym.2010.10.002","article-title":"Oral protein delivery: Current status and future prospect","volume":"71","author":"Park","year":"2011","journal-title":"React. Funct. Polym."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","article-title":"Angiogenesis in cancer","volume":"2","author":"Nishida","year":"2006","journal-title":"Vasc Health Risk Manag."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hooper, L., Anderson, A.S., Birch, J., Forster, A.S., Rosenberg, G., Bauld, L., and Vohra, J. (2017). Public awareness and healthcare professional advice for obesity as a risk factor for cancer in the UK: a cross-sectional survey. J. Public Health, 1\u20139.","DOI":"10.1093\/pubmed\/fdx145"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10549-017-4178-8","article-title":"Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study","volume":"163","author":"Conway","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.2016.418","article-title":"Smoking and risk of ovarian cancer by histological subtypes: An analysis among 300,000 Norwegian women","volume":"116","author":"Licaj","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/ijc.30009","article-title":"How do we judge what causes cancer? The meat controversy","volume":"138","author":"Vineis","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/stem.2571","article-title":"Low dose radiation causes skin cancer in mice and has a differential effect on distinct epidermal stem cells","volume":"35","author":"Revenco","year":"2017","journal-title":"Stem Cells"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10552-014-0377-3","article-title":"What causes breast cancer? A systematic review of causal attributions among breast cancer survivors and how these compare to expert-endorsed risk factors","volume":"25","author":"Hutchinson","year":"2014","journal-title":"Cancer Causes Control"},{"key":"ref_29","unstructured":"Holban, A.M., and Grumezescu, G. (2016). Multifunctional magnetic liposomes for cancer imaging and therapeutic applications. Nanoarchitectonics Smart Delivery Drug Targeting, Elsevier."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1016\/j.biomaterials.2013.01.078","article-title":"The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer","volume":"34","author":"Zhou","year":"2013","journal-title":"Biomaterials"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/HP.S133231","article-title":"A review of the development of tumor vasculature and its effects on the tumor microenvironment","volume":"5","author":"Forster","year":"2017","journal-title":"Hypoxia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0031-6997(24)01426-1","article-title":"Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors","volume":"51","author":"Drummond","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"ref_33","first-page":"331","article-title":"Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor","volume":"85","author":"Maeda","year":"1994","journal-title":"Cancer Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"16051","DOI":"10.1016\/S0021-9258(18)37555-0","article-title":"Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer","volume":"263","author":"Maeda","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_35","first-page":"1327","article-title":"Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue","volume":"79","author":"Matsumura","year":"1988","journal-title":"Cancer Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11912-004-0021-6","article-title":"Vascular targeting agents","volume":"6","author":"Pilat","year":"2004","journal-title":"Curr. Oncol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3923\/pjbs.2006.1181.1191","article-title":"Liposome as a carrier for advanced drug delivery","volume":"9","author":"Shaheen","year":"2006","journal-title":"Pak J. Biol. Sci."},{"key":"ref_39","first-page":"402","article-title":"Stability aspects of liposomes","volume":"45","author":"Yadav","year":"2011","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13346-015-0220-8","article-title":"Influence of cholesterol on liposome stability and on in vitro drug release","volume":"5","author":"Briuglia","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_41","first-page":"25","article-title":"The Effects of Lyophilization on the Physico-Chemical Stability of Sirolimus Liposomes","volume":"3","author":"Ghanbarzadeh","year":"2013","journal-title":"Adv. Pharm. Bull."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/IJN.S123062","article-title":"Achieving long-term stability of lipid nanoparticles: Examining the effect of pH, temperature, and lyophilization","volume":"12","author":"Ball","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pupt.2013.07.006","article-title":"Single step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach","volume":"27","author":"Pokharkar","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_44","first-page":"365","article-title":"Characterization and stability studies of a novel liposomal cyclosporin A prepared using the supercritical fluid method: Comparison with the modified conventional Bangham method","volume":"8","author":"Karn","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1021\/la00009a016","article-title":"A rigorous theory of remote loading of drugs into liposomes","volume":"11","author":"Ceh","year":"1995","journal-title":"Langmuir"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/jps.2600731118","article-title":"Influence of lipid composition and ionic strength on the physical stability of liposomes","volume":"73","author":"Crommelin","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"ref_47","unstructured":"Bundgaard, H., Bagger Hansen, A., and Kofod, H. (1982). Stability and storage of liposomes. Optimization of Drug Delivery, Munkgaard."},{"key":"ref_48","unstructured":"Gad, S.C. (2008). Pharmaceutical Nanosystems: Manufacture, characterisation and safety. Pharmaceutical Manufacturing Handbook: Production and Processes, John Wiley and Sons. Inc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9292","DOI":"10.1038\/srep09292","article-title":"Role of liposome and peptide in the synergistic enhancement of transfection with a lipopolyplex vector","volume":"5","author":"Munye","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-4157(76)90008-3","article-title":"The function of sterols in membranes","volume":"457","author":"Demel","year":"1976","journal-title":"Biochim. Biophys. Acta BBA-Biomembr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.foodchem.2017.03.021","article-title":"Kinetic stability and membrane structure of liposomes during in vitro infant intestinal digestion: Effect of cholesterol and lactoferrin","volume":"230","author":"Liu","year":"2017","journal-title":"Food Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/22103031113036660015","article-title":"Liposomes: Targeted and Controlled Delivery System","volume":"4","author":"Garg","year":"2014","journal-title":"Drug Del. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/bi00727a026","article-title":"Microviscosity and order in the hydrocarbon region of phospholipid and phospholipid-cholesterol dispersions determined with fluorescent probes","volume":"12","author":"Cogan","year":"1973","journal-title":"Biochemistry."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.fct.2018.01.017","article-title":"Cholesterol modulates the liposome membrane fluidity and permeability for a hydrophilic molecule","volume":"113","author":"Kaddah","year":"2018","journal-title":"Food Chem. Toxicol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Riaz, M.K., Riaz, M.A., Zhang, X., Lin, C., Wong, K.H., Chen, X., Zhang, G., Lu, A., and Yang, Z. (2018). Surface functionalization and targeting strategies of liposomes in solid tumor therapy: A review. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010195"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Catala, A. (2017). Thermosensitive Liposomes. Liposomes, InTech.","DOI":"10.5772\/66243"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzyme Regul."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"10907","DOI":"10.1021\/cr500314d","article-title":"Noninvasive imaging of nanomedicines and nanotheranostics: Principles, progress, and prospects","volume":"115","author":"Kunjachan","year":"2015","journal-title":"Chem. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(99)00042-3","article-title":"Possibility of active targeting to tumor tissues with liposomes","volume":"40","author":"Maruyama","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1126\/science.432641","article-title":"Liposomes and local hyperthermia: Selective delivery of methotrexate to heated tumors","volume":"204","author":"Weinstein","year":"1979","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1126\/science.364652","article-title":"Design of liposomes for enhanced local release of drugs by hyperthermia","volume":"202","author":"Yatvin","year":"1978","journal-title":"Science"},{"key":"ref_62","first-page":"123","article-title":"Fate and behavior of liposomes in vivo: A review of controlling factors","volume":"3","author":"Senior","year":"1987","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(97)00128-2","article-title":"Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo","volume":"32","author":"Cullis","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_64","first-page":"6950","article-title":"Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release","volume":"60","author":"Kong","year":"2000","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1023\/A:1016206631006","article-title":"Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma","volume":"12","author":"Gaber","year":"1995","journal-title":"Pharm. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0005-2736(94)90325-5","article-title":"Novel pH-sensitive liposomes: liposomes bearing a poly(ethylene glycol) derivative with carboxyl groups","volume":"1193","author":"Kono","year":"1994","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1039\/C6IB00234J","article-title":"Biocompatibility and therapeutic evaluation of magnetic liposomes designed for self-controlled cancer hyperthermia and chemotherapy","volume":"9","author":"Gogoi","year":"2017","journal-title":"Integr. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/1556-276X-9-497","article-title":"Magnetic liposomes for colorectal cancer cells therapy by high-frequency magnetic field treatment","volume":"9","author":"Hardiansyah","year":"2014","journal-title":"Nanoscale Res. Lett."},{"key":"ref_69","first-page":"3857","article-title":"Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade","volume":"7","author":"Graff","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1002\/1097-0142(19930515)71:10<3058::AID-CNCR2820711028>3.0.CO;2-8","article-title":"Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells","volume":"71","author":"Yamashita","year":"1993","journal-title":"Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF02795199","article-title":"Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas","volume":"13","author":"Kiyohara","year":"1993","journal-title":"Int. J. Pancreatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.bjc.6601725","article-title":"Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera","volume":"90","author":"Marrazzo","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_73","first-page":"69","article-title":"The role of gelatinases in colorectal cancer progression and metastasis","volume":"1705","author":"Mook","year":"2004","journal-title":"Biochim. Biophys. Acta BBA-Rev. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-4598-2-14","article-title":"Invasion and metastasis in pancreatic cancer","volume":"2","author":"Keleg","year":"2003","journal-title":"Mol. Cancer"},{"key":"ref_75","first-page":"202","article-title":"Hypoxia level and matrix metalloproteinases-2 and -9 activity in Lewis lung carcinoma: correlation with metastasis","volume":"27","author":"Osinsky","year":"2005","journal-title":"Exp. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"17976","DOI":"10.1074\/jbc.M011085200","article-title":"Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin","volume":"276","author":"Liu","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/187152012800617696","article-title":"Neutrophil elastase as a target in lung cancer","volume":"12","author":"Moroy","year":"2012","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jlb.57.3.375","article-title":"Free-form neutrophil elastase is an independent marker predicting recurrence in primary breast cancer","volume":"57","author":"Yamashita","year":"1995","journal-title":"J. Leukoc. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/1523-1747.ep12329559","article-title":"Inhibition of neutrophil elastase suppresses the development of skin tumors in hairless mice","volume":"107","author":"Starcher","year":"1996","journal-title":"J. Invest. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pros.1075","article-title":"Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models","volume":"48","author":"Denmeade","year":"2001","journal-title":"Prostate"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/14728222.2013.740461","article-title":"Cathepsin B as a cancer target","volume":"17","author":"Gondi","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acs.bioconjchem.6b00736","article-title":"Enzyme-responsive liposomes for the delivery of anticancer drugs","volume":"28","author":"Fouladi","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"8856","DOI":"10.1158\/1078-0432.CCR-05-1365","article-title":"Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model","volume":"11","author":"Arnold","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2006.07.8956","article-title":"European perspective on the costs and cost-effectiveness of cancer therapies","volume":"25","author":"Drummond","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/bjc.1994.229","article-title":"Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency","volume":"69","author":"Yamashita","year":"1994","journal-title":"Br. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1039\/c2ib20108a","article-title":"Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer","volume":"5","author":"Mock","year":"2013","journal-title":"Integr. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/252252a0","article-title":"Liposomes as immunological adjuvants","volume":"252","author":"Allison","year":"1974","journal-title":"Nature"},{"key":"ref_88","unstructured":"Mathe, G., Florentin, I., and Simmler, M.S. (1976). Liposomes as Immunological Adjuvants. Lymphocytes, Macrophages, and Cancer, Springer. Recent Results in Cancer Research\/Fortschritte der Krebsforschung\/Progr\u00e8s dans les recherches sur le cancer."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2051013614541440","article-title":"Liposomes as vaccine delivery systems: A review of the recent advances","volume":"2","author":"Schwendener","year":"2014","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hon.2386","article-title":"Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study","volume":"36","author":"Ricciuti","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2174\/1389200217666160728152939","article-title":"Delivery of nanoparticles for treatment of brain tumor","volume":"17","author":"Kang","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.18088\/ejbmr.2.1.2016.pp8-14","article-title":"Nanosized camptothecin conjugates for single and combined drug delivery","volume":"2","author":"Kang","year":"2016","journal-title":"Eur. J. Biomed. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CAD.0000000000000182","article-title":"Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes","volume":"26","author":"Tahover","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-2000-11124","article-title":"S-allylcysteine ameliorates doxorubicin toxicity in the heart and liver in mice","volume":"66","author":"Mostafa","year":"2000","journal-title":"Planta Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.8-suppl_2-17","article-title":"Cardiac Safety of Liposomal Anthracyclines","volume":"8","author":"Safra","year":"2003","journal-title":"Oncologist"},{"key":"ref_97","first-page":"277","article-title":"Liposomal daunorubicin as treatment for Kaposi\u2019s sarcoma","volume":"2","author":"Petre","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jddst.2017.04.005","article-title":"Pharmacokinetics and therapeutic efficiency of a novel cationic liposome nano-formulated all trans retinoic acid in lung cancer mice model","volume":"39","author":"Viswanathan","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_99","first-page":"653","article-title":"Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines\u2014in vitro studies","volume":"9","author":"Legut","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial","volume":"387","author":"Li","year":"2016","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.05.036","article-title":"State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines","volume":"187","author":"Dawidczyk","year":"2014","journal-title":"J. Control Release"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","article-title":"Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma","volume":"14","author":"Dimopoulos","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control Release."},{"key":"ref_104","first-page":"361","article-title":"Bioequivalence study of pegylated doxorubicin hydrochloride liposome (PEGADRIA) and DOXIL\u00ae in ovarian cancer patients: physicochemical characterization and pre-clinical studies","volume":"7","author":"Ali","year":"2016","journal-title":"J. Nanomed. Nanotechnol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","article-title":"Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi\u2019s sarcoma","volume":"14","author":"Gill","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s002800051025","article-title":"The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi\u2019s sarcoma","volume":"45","author":"Fumagalli","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO.1998.16.10.3369","article-title":"Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi\u2019s sarcoma","volume":"16","author":"Tulpule","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2013-02-484097","article-title":"Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from Study AML-BFM 2004","volume":"122","author":"Creutzig","year":"2013","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"13374","DOI":"10.1021\/acs.analchem.7b03568","article-title":"Investigation of cytotoxic activity of mitoxantrone at the individual cell level by using ionic-liquid-tag-enhanced mass spectrometry","volume":"89","author":"Kucherov","year":"2017","journal-title":"Anal. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00003088-199018050-00003","article-title":"Pharmacokinetics and metabolism of mitoxantrone A Review","volume":"18","author":"Ehninger","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"ref_111","first-page":"194","article-title":"Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model","volume":"52","author":"Alderton","year":"1992","journal-title":"Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.7314\/APJCP.2013.14.4.2591","article-title":"Clinical comparison between paclitaxel liposome (Lipusu\u00ae) and paclitaxel for treatment of patients with metastatic gastric cancer","volume":"14","author":"Xu","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"623139","DOI":"10.5402\/2012\/623139","article-title":"Designing paclitaxel drug delivery systems aimed at improved patient outcomes: Current status and challenges","volume":"2012","author":"Surapaneni","year":"2012","journal-title":"ISRN Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0378-5173(01)00986-3","article-title":"Paclitaxel and its formulations","volume":"235","author":"Singla","year":"2002","journal-title":"Int. J. Pharm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/cdd.1986.3.223","article-title":"Effect of vesicle size on the clearance, distribution, and tumor uptake of temperature-sensitive liposomes","volume":"3","author":"Magin","year":"1986","journal-title":"Cancer Drug Deliv."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/4\/907\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:00:45Z","timestamp":1760194845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/4\/907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,14]]},"references-count":115,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4]]}},"alternative-id":["molecules23040907"],"URL":"https:\/\/doi.org\/10.3390\/molecules23040907","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,14]]}}}